KRYS News and Press, Krystal Biotech Inc. From 08/08/22

Krystal Biotech press release ( NASDAQ: KRYS ): Q2 GAAP EPS of -$1.10 misses by $0.07 . Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments. For further details see: Krystal Biotech GAAP EPS of -$1.10 misses...

Biologics License Application for B-VEC filed with the FDA on June 22, 2022 FDA accepts IND on KB407 for the treatment of Cystic Fibrosis Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments PITTSBURGH, Aug. 08, 2022 (GLOBE ...

Krystal Biotech ( NASDAQ: KRYS ) said the U.S. Food and Drug Administration (FDA) accepted its investigational new drug application to start a trial of its gene therapy KB407 for cystic fibrosis (CF), a type of lung disorder. The company noted that KB407 is a...

KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), t...

While the broader market is struggling, Krystal Biotech (NASDAQ: KRYS) is performing relatively well. Shares of the gene-editing specialist are in the green for the year. It's been a volatile ride, though, and there could be more twists and turns for Krystal Biotech in the next 10 m...

PITTSBURGH, July 06, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the William Blair Biotech Focus Conference 2022 taking place in New York from ...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

The European Commission (EC) approved Amryt's ( NASDAQ: AMYT ) Filsuvez to treat partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare disease in which the skin becomes fragile an...

Krystal Biotech (NASDAQ:KRYS) said it submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its gene therapy B-VEC to treat patients with dystrophic epidermolysis bullosa (DEB). DEB is a rare disease in which the skin becomes fragile and can tear or blist...

PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking appr...